Aptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity

Reuters

2025/06/18

Aptevo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity

SEATTLE, WA / ACCESS Newswire / June 18, 2025 - Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company in the clinical development stage, has announced new clinical data from its Phase 1b/2 RAINIER trial. The trial evaluates mipletamig, a CD123 x CD3 bispecific antibody, in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia $(AML.AU)$ patients unfit for intensive chemotherapy. Results show an 85% remission rate among evaluable patients and a strong safety profile, with no dose-limiting toxicities observed. These findings suggest that mipletamig could significantly enhance standard AML treatment. The trial is nearing full enrollment for its third cohort at the highest dose level evaluated. The results were presented as part of the ongoing study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040816) on June 18, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2544974035"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544974035\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544974035?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-18 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544974035","market":"nz","top_or_hot":-1,"title":"Aptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SEATTLE, WA / ACCESS Newswire / June 18, 2025 - <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a> (Nasdaq: APVO), a biotechnology company in the clinical development stage, has announced new clinical data from its Phase 1b/2 RAINIER trial. The trial evaluates mipletamig, a CD123 x CD3 bispecific antibody, in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia <a href=\"https://laohu8.com/S/AML.AU\">$(AML.AU)$</a> patients unfit for intensive chemotherapy. Results show an 85% remission rate among evaluable patients and a strong safety profile, with no dose-limiting toxicities observed. These findings suggest that mipletamig could significantly enhance standard AML treatment. The trial is nearing full enrollment for its third cohort at the highest dose level evaluated. The results were presented as part of the ongoing study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040816) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-18 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SEATTLE, WA / ACCESS Newswire / June 18, 2025 - <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a> (Nasdaq: APVO), a biotechnology company in the clinical development stage, has announced new clinical data from its Phase 1b/2 RAINIER trial. The trial evaluates mipletamig, a CD123 x CD3 bispecific antibody, in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia <a href=\"https://laohu8.com/S/AML.AU\">$(AML.AU)$</a> patients unfit for intensive chemotherapy. Results show an 85% remission rate among evaluable patients and a strong safety profile, with no dose-limiting toxicities observed. These findings suggest that mipletamig could significantly enhance standard AML treatment. The trial is nearing full enrollment for its third cohort at the highest dose level evaluated. The results were presented as part of the ongoing study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040816) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EBS","symbol_name":"Emergent Biosolutions","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL18xCyp:1","article_id":"2544974035","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544974035","pubTimestamp":1750248111,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire  on June 18, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EBS":"Emergent Biosolutions","BK4583":"猴痘概念","APVO":"Aptevo Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Aptevo Therapeutics宣布Mipletamig治疗一线AML的有希望的1b/2期试验结果，在没有增加毒性的情况下实现了85%的缓解率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":0.9,"APVO":0.9},"content_text":"Aptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity\n    \n\n        SEATTLE, WA / ACCESS Newswire / June 18, 2025 - Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company in the clinical development stage, has announced new clinical data from its Phase 1b/2 RAINIER trial. The trial evaluates mipletamig, a CD123 x CD3 bispecific antibody, in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia $(AML.AU)$ patients unfit for intensive chemotherapy. Results show an 85% remission rate among evaluable patients and a strong safety profile, with no dose-limiting toxicities observed. These findings suggest that mipletamig could significantly enhance standard AML treatment. The trial is nearing full enrollment for its third cohort at the highest dose level evaluated. The results were presented as part of the ongoing study.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040816) on June 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}